IMMUNE DESIGN CORP. Patent applications |
Patent application number | Title | Published |
20140314834 | GLA MONOTHERAPY FOR USE IN CANCER TREATMENT - The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen. | 10-23-2014 |
20140127247 | VACCINES FOR HSV-2 - Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects. | 05-08-2014 |
20140086947 | VACCINES FOR HSV-2 - Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects. | 03-27-2014 |
20120328655 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR INDUCING HUMORAL AND CELLULAR IMMUNE RESPONSES - Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial. | 12-27-2012 |
20120288515 | SYNTHETIC LONG PEPTIDE (SLP)-BASED VACCINES - Synthetic long peptides and an adjuvant are formulated together and administered to a subject in order to raise an immune response. In certain embodiments, the adjuvant is GLA. | 11-15-2012 |
20120263754 | Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines - Provided herein are methods for inducing a specific immune response in a subject by administering to the subject an immunogenic composition comprising a recombinant expression vector, or a vector particle comprising the recombinant expression vector, which vector comprises a polynucleotide sequence that encodes an immunogen of interest. The methods further comprise administering an adjuvant composition either concurrently or sequentially with the immunogenic composition. | 10-18-2012 |
20120039932 | Lentiviral Vectors Pseudotyped with a Sindbis Virus Envelope Glycoprotein - Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain). | 02-16-2012 |
20110305748 | Vaccines for Pandemic Influenza - Pharmaceutical and vaccine compositions comprise recombinant hemagglutinin from a pre-pandemic or pandemic influenza virus and an adjuvant comprising GLA. A particularly relevant pre-pandemic influenza virus is H5N1. Kits and methods of using the compositions are also provided. | 12-15-2011 |
20110064763 | LENTIVIRAL VECTORS PSEUDOTYPED WITH A SINDBIS VIRUS ENVELOPE GLYCOPROTEIN - Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain). | 03-17-2011 |